Semaglutide vs Ozempic vs Wegovy: What's the Difference?

The Simple Answer (Then We'll Explain)

Semaglutide is the active drug. Ozempic and Wegovy are brand names for that same drug, just marketed for different purposes with different dosing schedules.

Think of it like ibuprofen (the drug) being sold as Advil or Motrin (the brand names). Same medication, different packaging and marketing.

Breaking Down Each Option

Ozempic (Semaglutide for Diabetes)

FDA Approval: Type 2 diabetes management

Available Doses: 0.25mg, 0.5mg, 1mg, 2mg

Typical Cost: $900-$1,000/month without insurance

Ozempic was the first semaglutide product to hit the market (2017). It's specifically indicated for improving blood sugar control in adults with type 2 diabetes. The weight loss that occurred in clinical trials was technically a "side effect," though obviously a welcomed one.

Many doctors prescribe Ozempic off-label for weight loss because it contains the exact same medication as Wegovy, just typically at lower maximum doses.

Wegovy (Semaglutide for Weight Loss)

FDA Approval: Chronic weight management

Available Doses: 0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg

Typical Cost: $1,200-$1,400/month without insurance

Wegovy received FDA approval in 2021 specifically for weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition.

The key difference? Wegovy goes up to 2.4mg—a higher maintenance dose than Ozempic's typical 1mg or 2mg. That extra 0.4mg can make a noticeable difference in weight loss outcomes for some people.

Compounded Semaglutide (Generic Alternative)

Regulation: Made by licensed compounding pharmacies under FDA oversight

Available Doses: Customizable, typically matching Wegovy's dosing schedule

Typical Cost: $199-$345/month

Compounded semaglutide has become popular due to ongoing shortages of brand-name versions and significantly lower costs. These are made by specialized pharmacies that create medications from raw ingredients under strict quality standards.

The Dosing Differences That Actually Matter

Both Ozempic and Wegovy use the same titration (gradual dose increase) approach to minimize side effects:

The difference between 1mg (typical Ozempic) and 2.4mg (Wegovy) resulted in about 5-7% more body weight loss in clinical trials. For someone weighing 200 pounds, that's an additional 10-14 pounds of weight loss on average.

Which One Should You Choose?

Choose Ozempic If:

• You have type 2 diabetes (it's approved for this)
• Your insurance covers Ozempic but not Wegovy
• You're trying the medication off-label for weight loss and want to start conservatively
• You experience side effects at lower doses and don't want to go higher

Choose Wegovy If:

• You're primarily focused on weight loss (it's specifically approved)
• You want the full 2.4mg dosing option
• Your insurance covers weight loss medications
• You want to avoid "off-label" use

Choose Compounded Semaglutide If:

• Cost is a major factor ($199-$345 vs $900-$1,400)
• You don't have insurance coverage for weight loss medications
• You want access to the full Wegovy dosing schedule
• Brand name shortages are affecting availability in your area

The Insurance Coverage Complication

Here's where things get messy: many insurance plans cover Ozempic for diabetes but explicitly exclude Wegovy for weight loss. This has led to a few workarounds:

Safety Profile: Any Differences?

No. Since they're the same medication, they have the same safety profile, side effects, and contraindications. Common side effects include:

• Nausea (usually temporary during dose increases)
• Diarrhea or constipation
• Abdominal discomfort
• Decreased appetite (this is partly how it works)
• Occasional vomiting

The main difference in side effect experience comes from dosing—higher doses (like Wegovy's 2.4mg) may produce more pronounced side effects in some individuals.

What About Rybelsus?

Rybelsus is another brand name for semaglutide—but it's an oral tablet instead of an injection. It's approved for type 2 diabetes but requires daily dosing and tends to be less effective for weight loss compared to the injectable versions.

Most people serious about weight loss stick with the weekly injections (Ozempic, Wegovy, or compounded semaglutide) rather than daily oral tablets.

Same Molecule, Different Brand: The Cornerstone Insight

The single most important fact about semaglutide vs Ozempic vs Wegovy is this: all three contain the same active pharmaceutical ingredient — semaglutide — at the molecular level. Semaglutide is a GLP-1 receptor agonist that mimics the endogenous incretin hormone glucagon-like peptide-1, slowing gastric emptying, increasing satiety, and improving glycemic control.

According to the FDA prescribing information for both Wegovy and Ozempic, the active ingredient is identical. What differs:

• Manufacturer and brand: Novo Nordisk markets Ozempic and Wegovy under separate brand names with separate New Drug Applications.
• FDA-approved indication: Ozempic for type 2 diabetes and cardiovascular risk reduction; Wegovy for chronic weight management.
• Dosing schedule: Ozempic tops out at 2 mg/week; Wegovy escalates to 2.4 mg/week.
• Insurance coverage: Diabetes plans cover Ozempic; commercial weight-management benefits sometimes cover Wegovy.
• Form factor and packaging: Both are pre-filled pens; compounded semaglutide is typically supplied in vials.

Because the active ingredient is identical, compounded semaglutide prepared at a 503A community sterile compounding pharmacy can be formulated at the same molecular efficacy as the brand-name products. The medication is the same — the regulatory wrapper, the price, and the FDA indication are what diverge.

Side-by-Side Comparison Table

The table below summarizes how generic semaglutide, Ozempic, Wegovy, and Trimi's compounded semaglutide compare across the dimensions clinicians and patients ask about most.

FDA-Approved Indication: What Each Brand Is Actually For

The FDA approves drugs for specific clinical uses based on the trials submitted in the New Drug Application. The indication is what the manufacturer can market the drug for and what most insurance plans will cover.

Ozempic

Per FDA prescribing information, Ozempic is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. In 2020, the FDA expanded the indication to include reduction of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) in adults with type 2 diabetes and established cardiovascular disease.

Wegovy

Per FDA prescribing information, Wegovy is approved for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m² or greater (obesity), or 27 kg/m² or greater (overweight) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia. In 2024, the FDA expanded Wegovy's indication to include reduction of cardiovascular risk in adults with obesity or overweight and established cardiovascular disease.

Compounded semaglutide

Compounded semaglutide is not FDA-approved as a finished drug product. The active ingredient — semaglutide — is FDA-approved in the commercial Ozempic and Wegovy products. 503A community sterile compounding pharmacies prepare semaglutide for individual patients pursuant to a valid prescription, under state pharmacy board oversight and in accordance with USP <797> sterile compounding standards.

Dosing Schedule: Ozempic vs Wegovy vs Compounded

All three products use a four-week titration cadence to minimize gastrointestinal side effects. The schedules diverge above 1 mg.

Compounded semaglutide programs typically follow the Wegovy schedule when the goal is weight loss, allowing patients to reach the 2.4 mg dose that drove the strongest outcomes in the STEP 1 trial.

Clinical Evidence: What the Trials Actually Show

Three pivotal randomized controlled trials anchor the clinical evidence base for semaglutide.

STEP 1 (Wilding et al., NEJM 2021)

According to the STEP 1 trial published in the New England Journal of Medicine in 2021, semaglutide 2.4 mg once weekly produced a mean body-weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% in the placebo group. The trial enrolled 1,961 adults with overweight or obesity and no diabetes.

SUSTAIN program

The SUSTAIN trials — a series of phase 3 studies in adults with type 2 diabetes — demonstrated that semaglutide significantly reduced HbA1c and body weight versus placebo and active comparators including sitagliptin, exenatide ER, insulin glargine, and dulaglutide. These trials supported Ozempic's FDA approval for glycemic control.

SELECT (Lincoff et al., NEJM 2023)

According to the SELECT trial published in the New England Journal of Medicine in 2023, semaglutide 2.4 mg reduced major adverse cardiovascular events by approximately 20% in adults with overweight or obesity and established cardiovascular disease but without diabetes. This trial directly supported Wegovy's 2024 cardiovascular indication expansion.

Per the FDA prescribing information for Wegovy, the magnitude of weight loss observed at the 2.4 mg dose was the basis for the chronic weight management indication. Results vary based on starting weight, dose tolerated, adherence, diet, and exercise.

What About Compounded Semaglutide?

Compounded semaglutide contains the same active ingredient as Ozempic and Wegovy — the molecular structure is identical. The difference is regulatory: brand-name products go through the FDA's New Drug Application pathway, while compounded semaglutide is prepared by 503A community sterile compounding pharmacies for individual patients under a valid prescription.

Trimi's compounded semaglutide is dispensed by VialsRx (Texas State Board of Pharmacy license #35264) and GreenwichRx, both 503A facilities operating under USP <797> sterile compounding standards. Clinical oversight is provided through Beluga Health, the multistate clinician network behind Trimi's prescribing infrastructure.

Important distinction: Compounded semaglutide is not FDA-approved as a finished drug product. The active ingredient is FDA-approved in commercial Ozempic and Wegovy. This is the same regulatory framework that governs every compounded medication dispensed in the United States.

On price: Trimi offers compounded semaglutide at $99/month on the annual plan, compared with approximately $1,349/month for Wegovy retail. For the most current breakdown of legal cash-pay options, see our reference on finding the most affordable compliant GLP-1 routes.

GLP-1 Risks You Should Know Before Starting

Semaglutide — under any brand or compounded preparation — carries the same risk profile because the active molecule is identical. Common and serious adverse effects include:

• Common side effects: nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite. These are typically dose-dependent and most pronounced during titration.
• Gallbladder disease: increased risk of cholelithiasis and acute cholecystitis, particularly during rapid weight loss.
• Pancreatitis: acute pancreatitis has been reported in semaglutide users; patients with a personal history should avoid GLP-1 therapy.
• Acute kidney injury: dehydration secondary to nausea and vomiting can precipitate AKI; volume status should be monitored.
• FDA boxed warning — thyroid C-cell tumors: semaglutide causes thyroid C-cell tumors in rodents. The product is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).

This is general information, not medical advice. Every prospective semaglutide patient should be evaluated by a licensed clinician who can review personal and family history, current medications, and contraindications before prescribing.

The Bottom Line

If you're confused by all the names, just remember: Ozempic, Wegovy, and compounded semaglutide are all the same drug. The differences are in:

• FDA indication: Diabetes vs weight loss
• Maximum dose: 2mg vs 2.4mg
• Cost: $900-$1,400 (brand) vs $199-$345 (compounded)
• Insurance coverage: Varies wildly by plan

For most people seeking weight loss without diabetes, compounded semaglutide offers the best combination of effectiveness, affordability, and access.